AEterna Zentaris (AEterna Zentaris) Total Payout Ratio : 0.00 (As of Apr. 28, 2024)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

AEterna Zentaris's current Total Payout Ratio is 0.00.

AEterna Zentaris Total Payout Ratio Historical Data

The historical data trend for AEterna Zentaris's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Total Payout Ratio Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Ratio

Get a 7-Day Free Trial

0.83

4.59

4.09

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of AEterna Zentaris's Total Payout Ratio

For the Biotechnology subindustry, AEterna Zentaris's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Total Payout Ratio falls into.

AEterna Zentaris Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

AEterna Zentaris's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-16.552
	=	0.00

AEterna Zentaris's Total Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-5.635
	=	0.00

AEterna Zentaris Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.